Article
Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?
Drug metabolism and personalized therapy - 1 Sept 2016
Falvella Felicia Stefania, Marelli Susan, Cheli Stefania, Montanelli Stefano, Viecca Federico, Salvi Lucia, Ferrara Alfio, Clementi Emilio, Trifirò Giuliana, Pini Alessandro
Abstract excerpt
BACKGROUND: Losartan is under evaluation for managing Marfan patients with aortic root dilatation. Cytochrome P450 (CYP) enzymes convert losartan to E3174 active metabolite. The aim of this study is to describe the distribution of CYP2C9*2, CYP2C9*3, CYP3A4*22 and CYP3A5*3 defective alleles, according to losartan tolerance in paediatric Marfan patients. METHODS: We genotyped 53 paediatric Marfan patients treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.